Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;54(7):1411-7.
doi: 10.3109/10428194.2012.745525. Epub 2012 Dec 5.

Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009

Yiming Chen  1 , Haijun Wang, Hagop Kantarjian, Jorge Cortes
Affiliations

Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009

Yiming Chen et al. Leuk Lymphoma. 2013 Jul.

Abstract

The use of interferon-α and allogeneic stem cell transplant and more recently of tyrosine kinase inhibitors (TKIs) have improved the outcome of patients with chronic myeloid leukemia (CML). We performed a population-based study of CML to evaluate relative survival (RS) trend by treatment eras. All instances of CML diagnosed between 1975 and 2009 reported in the Surveillance, Epidemiology and End Results databases were reviewed. The incidence of CML was 1.75/100 000 persons per year and increased with age. The incidence was highest in Detroit and lowest among Asians. The 5-year RS ratios increased from 0.26 in patients diagnosed in 1975-1989 to 0.36 in 1990-2000 and 0.56 in 2001-2009. There was a significant improvement in 5-year RS ratios in the 2005-2009 calendar period compared to the 2001-2004 period (p < 0.05), corresponding to the introduction of second-generation TKIs. Age was the most important prognostic factor for RS, but the improvement in 5-year RS ratios was observed in all age groups except the group aged < 15 years (p > 0.05), including adolescents and young adults and elderly patient groups. There are ethnic and geographic variations in the incidence of CML. The RS improved with each treatment era, with the greatest improvement in all age groups occurring during the TKI era.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: none

Figures

Fig 1
Fig 1
(A) Cumulative relative survival of all patients with chronic myeloid leukemia by calendar period of diagnosis. (B) Cumulative relative survival of patients with chronic myeloid leukemia during 2001–2004 versus 2005–2009
Fig 1
Fig 1
(A) Cumulative relative survival of all patients with chronic myeloid leukemia by calendar period of diagnosis. (B) Cumulative relative survival of patients with chronic myeloid leukemia during 2001–2004 versus 2005–2009
Fig 2
Fig 2
Relative survival in patients with chronic myeloid leukemia by age and calendar period of diagnosis
Fig 2
Fig 2
Relative survival in patients with chronic myeloid leukemia by age and calendar period of diagnosis
Fig 2
Fig 2
Relative survival in patients with chronic myeloid leukemia by age and calendar period of diagnosis
Fig 3
Fig 3
One-, 5-, and 10-year relative survival in patients with chronic myeloid leukemia by age group and calendar period of diagnosis
Fig 3
Fig 3
One-, 5-, and 10-year relative survival in patients with chronic myeloid leukemia by age group and calendar period of diagnosis
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300. Prepublished on 2010/07/09 as DOI caac.20073 [pii] 10.3322/caac.20073. - PubMed
    1. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med. 2007;357(3):258–265. Prepublished on 2007/07/20 as DOI 357/3/258 [pii] 10.1056/NEJMct071828. - PubMed
    1. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet. 2007;370(9584):342–350. Prepublished on 2007/07/31 as DOI S0140-6736(07)61165-9 [pii] 10.1016/S0140-6736(07)61165-9. - PubMed
    1. Peggs K, Mackinnon S. Imatinib mesylate–the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med. 2003;348(11):1048–1050. Prepublished on 2003/03/15 as DOI 10.1056/NEJMe030009348/11/1048 [pii] - PubMed
    1. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med. 1994;330(12):820–825. doi: 10.1056/NEJM199403243301204. Prepublished on 1994/03/24. - DOI - PubMed

Publication types

MeSH terms